Therapies for HCC and Cholangiocarcinoma

Monday, March 6, 2023

8:30 AM – 10:00 AM

Location:Phoenix Convention Center, 222AB

CE: 1.5 Credits

Coordinator(s)

Nadine Abi-Jaoudeh, MD, FSIR

Professor of Radiology
University of California

Disclosure(s): Angiodynamics Inc: Contracted Research (Ongoing); AstraZeneca: Consultant (Ongoing); BlackSwan Vascular Inc: Contracted Research (Terminated, November 7, 2022); Bruin Biosciences Inc.: Ownership Interest (Ongoing); Eisai Co., Ltd: Advisory Committee or Review Panel Member (Terminated, April 15, 2021); Genentech F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Guerbet SA: Research Grant Recipient (Ongoing); Histosonics Inc.: Data safety Monitoring Board (Ongoing); Innova Vascular Inc: Advisory Committee or Review Panel Member (Ongoing); Instylla HES Inc: Contracted Research (Ongoing); Johnson and Johnson: Consultant (Ongoing); Lynx Group LLC: Advisory Committee or Review Panel Member (Terminated, January 27, 2022); Medtronic Inc: Advisory Committee or Review Panel Member (Terminated, April 30, 2021); Pfizer Inc: Advisory Committee or Review Panel Member (Terminated, October 15, 2021); Philips Medical Systems Inc Koninklijke NV: Research Grant Recipient (Ongoing); QED Therapeutics Inc: Advisory Committee or Review Panel Member (Terminated, February 1, 2021); Sirtex Medical Ltd: Contracted Research (Ongoing); Teclison Limited (PI): Research Grant Recipient (Ongoing)

Disclosure(s):

Nadine Abi-Jaoudeh, MD, FSIR: Angiodynamics Inc: Contracted Research (Ongoing); AstraZeneca: Consultant (Ongoing); BlackSwan Vascular Inc: Contracted Research (Terminated, November 7, 2022); Bruin Biosciences Inc.: Ownership Interest (Ongoing); Eisai Co., Ltd: Advisory Committee or Review Panel Member (Terminated, April 15, 2021); Genentech F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Guerbet SA: Research Grant Recipient (Ongoing); Histosonics Inc.: Data safety Monitoring Board (Ongoing); Innova Vascular Inc: Advisory Committee or Review Panel Member (Ongoing); Instylla HES Inc: Contracted Research (Ongoing); Johnson and Johnson: Consultant (Ongoing); Lynx Group LLC: Advisory Committee or Review Panel Member (Terminated, January 27, 2022); Medtronic Inc: Advisory Committee or Review Panel Member (Terminated, April 30, 2021); Pfizer Inc: Advisory Committee or Review Panel Member (Terminated, October 15, 2021); Philips Medical Systems Inc Koninklijke NV: Research Grant Recipient (Ongoing); QED Therapeutics Inc: Advisory Committee or Review Panel Member (Terminated, February 1, 2021); Sirtex Medical Ltd: Contracted Research (Ongoing); Teclison Limited (PI): Research Grant Recipient (Ongoing)

To review imaging biomarkers of primary liver cancers, updates on systemic, immunotherapies, locoregional therapies for HCC and cholangiocarcinoma as well as combination therapies

Learning Objectives:

Upon completion, participant will be able to define imaging criteria and outcome biomarkers for HCC interventions
Upon completion, participant will be able to describe existing systemic and locoregional therapies for HCC and cholangiocarcinoma
Upon completion, participant will describe upcoming locoregional intervention, combination therapies and systemic therapies for HCC

Presentations:

8:30 AM – 8:40 AM

Combination therapies in HCC & cholangiocarcinoma
Speaker: Nadine Abi-Jaoudeh, MD, FSIR – University of California
8:40 AM – 8:50 AM

Immune microenvironment and immunotherapies
Speaker: Farshid Dayyani, MD, PhD (he/him/his) – University of California Irvine
8:50 AM – 9:00 AM

Ablation for Primary Liver Cancer: Current and Upcoming technologies
Speaker: Susan Shamimi-Noori, MD – University of Pennsylvania
9:00 AM – 9:10 AM

Systemic therapies for HCC and cholangiocarcinoma
Speaker: Farshid Dayyani, MD, PhD (he/him/his) – University of California Irvine
9:10 AM – 9:20 AM

Imaging Challenges in Immunotherapies and Combination Therapies
Speaker: Dayantha Fernando, MD – University of California Irvine
9:20 AM – 9:30 AM

TARE for Y90: Latest trials
Speaker: Edward Kim, MD – Mount Sinai Health System
9:30 AM – 9:40 AM

TACE: past and future developments for primary liver tumors
Speaker: Sarah B. White, MD, MS, FSIR – Medical College of Wisconsin
9:40 AM – 9:50 AM

Experimental Platforms and Animal Models in HCC Imaging and Interventions
Speaker: Rony Avritscher, MD – MD Anderson Cancer Center
9:50 AM – 10:00 AM

Q & A